Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Schöffski, Patrick; Chawla, Sant; Maki, Robert G; Italiano, Antoine; Gelderblom, Hans; Choy, Edwin; Grignani, Giovanni; Camargo, Veridiana; Bauer, Sebastian; Rha, Sun Young; Blay, Jean-Yves; Hohenberger, Peter; D'Adamo, David; Guo, Matthew; Chmielowski, Bartosz; Le Cesne, Axel; Demetri, George D; Patel, Shreyaskumar R

doi:10.1016/S0140-6736(15)01283-0

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Author:

Schöffski, Patrick

Chawla, Sant ; Maki, Robert G ; Italiano, Antoine ; Gelderblom, Hans ; Choy, Edwin ; Grignani, Giovanni ; Camargo, Veridiana ; Bauer, Sebastian ; Rha, Sun Young ; Blay, Jean-Yves ; Hohenberger, Peter ; D'Adamo, David ; Guo, Matthew ; Chmielowski, Bartosz ; Le Cesne, Axel ; Demetri, George D ; Patel, Shreyaskumar R

Keywords:

Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, SOFT-TISSUE SARCOMA, DOUBLE-BLIND, MESYLATE, GEMCITABINE, ANTHRACYCLINE, CHEMOTHERAPY, IFOSFAMIDE, DOCETAXEL, PAZOPANIB, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Dacarbazine, Female, Furans, Humans, Ketones, Leiomyosarcoma, Liposarcoma, Male, Middle Aged, Neoplasm Grading, Soft Tissue Neoplasms, Survival Analysis, Treatment Outcome, Young Adult, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine (an active control).